Methimepip dihydrobromide

Discontinued Product

Unfortunately Methimepip dihydrobromide (Cat. No. 2947) has been withdrawn from sale for commercial reasons.
Cat.No. 2947 - Methimepip dihydrobromide | C10H17N3.2HBr | CAS No. 817636-54-7
Description: Extremely selective H3 agonist
Chemical Name: 4-(1H-Imidazol-4-ylmethyl)-1-methylpiperidine dihydrobromide

Biological Activity

Extremely selective histamine H3 receptor agonist (pKi values are 9.0, 5.7, < 5.0 and < 5.0 for hH3, hH4, hH1 and hH2 receptors respectively). Potently inhibits EFS-evoked contractions of guinea pig ileum (pD2 = 8.26).

Technical Data

M. Wt 341.09
Formula C10H17N3.2HBr
Storage Desiccate at RT
CAS Number 817636-54-7
PubChem ID 11313836
Smiles CN1CCC(CC2=CNC=N2)CC1.Br.Br

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Preparing Stock Solutions

The following data is based on the product molecular weight 341.09. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.93 mL 14.66 mL 29.32 mL
5 mM 0.59 mL 2.93 mL 5.86 mL
10 mM 0.29 mL 1.47 mL 2.93 mL
50 mM 0.06 mL 0.29 mL 0.59 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets

Safety Datasheet


References are publications that support the products' biological activity.

Kitbunnadaj et al (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J.Med.Chem. 48 2100 PMID: 15771452

View Related Products by Target

View Related Products by Product Action

View all Histamine H3 Receptor Agonists

Keywords: Methimepip dihydrobromide, supplier, selective, H3, agonists, Receptors, Histamine, histaminergic, Histamine, H3, Receptors, Histamine, H3, Receptors, Tocris Bioscience

Citations for Methimepip dihydrobromide

Citations are publications that use Tocris products.

Currently there are no citations for Methimepip dihydrobromide.

Reviews for Methimepip dihydrobromide

There are currently no reviews for this product. Be the first to review Methimepip dihydrobromide and earn rewards!

Have you used Methimepip dihydrobromide?

Submit a review and receive an Amazon gift card.

$10US/$10CAN/€7/£6 gift card for a review without an image

$25US/$25CAN/€18/£15 gift card for a review with an image

*Offer only valid in the USA / Canada, UK and Europe

Submit a Review

Literature in this Area


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Histamine Receptors

Histamine Receptors Scientific Review

Written by Iwan de Esch and Rob Leurs, this review provides a synopsis of the different histamine receptor subtypes and the ligands that act upon them; compounds available from Tocris are listed.


Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.


Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.